SGN-ALPV / Pfizer - LARVOL DELTA

SGNALPV-001: A Study of SGN-ALPV in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=43 | Terminated | Sponsor: Seagen Inc. | Trial completion date: Nov 2027 ➔ Dec 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2024 ➔ Dec 2023; Study closed due to portfolio prioritization

Metastases • Trial completion date • Trial primary completion date • Trial termination • Cervical Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Germ Cell Tumors • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • Testicular Cancer • Uterine Cancer

SGNALPV-001: A Study of SGN-ALPV in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=43 | Active, not recruiting | Sponsor: Seagen Inc. | Recruiting ➔ Active, not recruiting | N=305 ➔ 43

Enrollment change • Enrollment closed • Metastases • Cervical Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Germ Cell Tumors • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • Testicular Cancer • Uterine Cancer

Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress). (ASCO 2022) - P1 | "Enrollment for Part A is ongoing in sites in North America and Europe. Enrollment for Parts B and C will be opened upon completion of Part A."

P1 data • Cervical Cancer • Gastric Cancer • Genito-urinary Cancer • Germ Cell Tumors • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Testicular Cancer • ALPP

SGNALPV-001: A Study of SGN-ALPV in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=285 | Recruiting | Sponsor: Seagen Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cervical Cancer • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • Germ Cell Tumors • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • Testicular Cancer • Uterine Cancer

SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models (AACR 2022) - "SGN-ALPV was well tolerated in non-human primates (NHP) and exhibited linear pharmacokinetic characteristics, with a toxicity profile consistent with other vedotin-based ADCs. In summary, differential expression of ALPP and ALPPL2 in the tumor versus normal tissue, antibody specificity, antitumor activity, and tolerability of SGN-ALPV provide a strong rationale for the initiation of a planned first-in-human Phase 1 clinical study."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • ALPG • ALPP

Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting (Businesswire) - "Seagen...announced data from intravesical instillation of enfortumab vedotin (EV) in a non-muscle invasive bladder cancer (NMIBC) preclinical model in addition to preclinical data from SGN-ALPV and SGN-B7H4V, two of its novel antibody-drug conjugates (ADCs) that utilize the company’s proprietary vedotin drug linker technology....Studies with human bladder cancer cells expressing Nectin-4 showed sustained activity under conditions mimicking intravesical dosing and achieved tumor growth inhibition of 97% when administered in an orthotopic xenograft animal model of NMIBC."

Preclinical • Bladder Cancer • Oncology

Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting 04/08/2022 (Seagen Press Release) - "In preclinical studies, SGN-ALPV exhibited robust antitumor activity in cell line and patient-derived xenograft cancer models with both homogenous and heterogeneous expression of placental alkaline phosphatases ALPP and ALPPL2, consistent with robust monomethyl auristatin E (MMAE)-directed cytotoxicity and bystander activity of vedotin ADCs....SGN-B7H4V shows immunomodulatory activity through induction of immunogenic cell death."

Preclinical • Oncology